AG-120 is currently being evaluated in several clinical trials for the therapy of patients with relapsed or refractory AML, myelodysplastic syndrome, and advanced solid tumors including glioma, chondrosarcoma, and cholangiocarcinoma with a mutant IDH1/R132H (Table 1). This evidence concerns the gene IDH1 and myelodysplastic syndrome.